Aprea Therapeutics announced that it received formal notice from The Nasdaq Stock Market stating that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Global Select Market as set forth in Nasdaq Listing Rule 5450(a)(1) ."We are excited about regaining compliance and we believe our recent financing, which was supported by quality institutions, has strengthened our balance sheet and enabled the Company to continue developing its clinical asset, ATRN-119, and its pre-clinical asset ATRN-W1051" said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on APRE:
- Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
- Aprea Therapeutics 1.05M share Spot Secondary priced at $5.25
- Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
- Aprea Therapeutics proposes public offering of common stock, amount not stated
